---
title: "Mizuho Securities Sticks to Their Hold Rating for Athira Pharma (ATHA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/270227414.md"
description: "Mizuho Securities analyst Graig Suvannavejh maintains a Hold rating for Athira Pharma with a $4.00 price target. Suvannavejh, a 5-star analyst with a 16.6% average return, covers the Healthcare sector. The consensus among analysts is a Hold rating for Athira Pharma, with a $4.00 average price target."
datetime: "2025-12-19T00:15:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270227414.md)
  - [en](https://longbridge.com/en/news/270227414.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270227414.md)
generator: "portal-rs"
---

# Mizuho Securities Sticks to Their Hold Rating for Athira Pharma (ATHA)

Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Athira Pharma yesterday and set a price target of $4.00.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

According to TipRanks, Suvannavejh is a 5-star analyst with an average return of 16.6% and a 49.90% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Insmed, and EyePoint Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Athira Pharma with a $4.00 average price target.

### Related Stocks

- [ATHA.US](https://longbridge.com/en/quote/ATHA.US.md)
- [LONA.US](https://longbridge.com/en/quote/LONA.US.md)

## Related News & Research

- [LeonaBio Q2 net loss widens on higher R&D spending](https://longbridge.com/en/news/295971106.md)
- [LeonaBio targets Phase 3 ELAINE-3 enrollment completion in Q4 2026, topline data seen in H2 2027](https://longbridge.com/en/news/295655741.md)
- [LeonaBio spotlights lasofoxifene at DAVA Oncology breast cancer summit](https://longbridge.com/en/news/295654419.md)
- [Queen’s Road Capital publishes MD&A for nine months ended May 31, 2026](https://longbridge.com/en/news/292480941.md)
- [LeonaBio stockholders back Ernst & Young as 2026 auditor at annual meeting](https://longbridge.com/en/news/290603553.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**